- Home
- VNO vs JAZZ Comparison
VNO vs JAZZ Comparison
Compare VNO & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNO
- JAZZ
- Stock Information
- Founded
- VNO 1946
- JAZZ 2003
- Country
- VNO United States
- JAZZ Ireland
- Employees
- VNO N/A
- JAZZ N/A
- Industry
- VNO Real Estate Investment Trusts
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- VNO Real Estate
- JAZZ Health Care
- Exchange
- VNO Nasdaq
- JAZZ Nasdaq
- Market Cap
- VNO 7.0B
- JAZZ 6.7B
- IPO Year
- VNO N/A
- JAZZ 2007
- Fundamental
- Price
- VNO $38.60
- JAZZ $110.27
- Analyst Decision
- VNO Hold
- JAZZ Strong Buy
- Analyst Count
- VNO 11
- JAZZ 12
- Target Price
- VNO $37.91
- JAZZ $183.08
- AVG Volume (30 Days)
- VNO 2.0M
- JAZZ 667.5K
- Earning Date
- VNO 08-04-2025
- JAZZ 07-30-2025
- Dividend Yield
- VNO 1.92%
- JAZZ N/A
- EPS Growth
- VNO 248.25
- JAZZ 49.21
- EPS
- VNO 0.52
- JAZZ 7.51
- Revenue
- VNO $1,929,890,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- VNO N/A
- JAZZ $6.05
- Revenue Next Year
- VNO $4.97
- JAZZ $4.68
- P/E Ratio
- VNO $73.59
- JAZZ $14.68
- Revenue Growth
- VNO 2.98
- JAZZ 5.76
- 52 Week Low
- VNO $26.19
- JAZZ $95.49
- 52 Week High
- VNO $46.63
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- VNO 50.76
- JAZZ 52.75
- Support Level
- VNO $37.45
- JAZZ $109.27
- Resistance Level
- VNO $38.88
- JAZZ $112.70
- Average True Range (ATR)
- VNO 1.22
- JAZZ 2.72
- MACD
- VNO -0.05
- JAZZ 0.42
- Stochastic Oscillator
- VNO 59.66
- JAZZ 67.81
About VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.